Oncology

PROpel study backs Lynparza combo in first-line prostate cancer

https://pharmaphorum.com/news/propel-study-backs-lynparza-combo-in-first-line-prostate-cancer/

Boehringer buys Abexxa, bolstering its immuno-oncology pipeline

https://pharmaphorum.com/news/boehringer-buys-abexxa-bolstering-its-immuno-oncology-pipeline/

FDA clears Seagen, Genmab’s Tivdak ADC for cervical cancer

https://pharmaphorum.com/news/fda-clears-seagen-genmabs-tivdak-adc-for-cervical-cancer/

ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda

https://pharmaphorum.com/news/esmo21-libtayo-extends-survival-in-first-line-nsclc-challenging-keytruda/

ESMO21: Enhertu brings it’s A game to second-line breast cancer

https://pharmaphorum.com/news/esmo21-enhertu-brings-its-a-game-to-second-line-breast-cancer/

ESMO21: Roche’s giredestrant takes stage in battle of the oral SERDs

https://pharmaphorum.com/news/esmo21-roches-giredestrant-takes-stage-in-battle-of-the-oral-serds/

ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRC

https://pharmaphorum.com/news/esmo21-first-combo-data-with-amgens-lumakras-hit-the-mark-in-crc/

https://pharmaphorum.com/events/pm-society-digital-awards-2021/

First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab

https://pharmaphorum.com/news/first-fda-filing-for-novartis-latecomer-pd-1-drug-tislelizumab/

1 2 3 4 5 >»

Close in 10 seconds

Pharmaphorum.com

Search